Fox Chase | Strategic Alliance Partners

Latest from Fox Chase

What Can Residents Learn From an Oncology Fellowship?

November 25, 2021

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss what the benefits are of an oncology fellowship and the takeaways and important lessons Nardello learned from his own breast oncology fellowship at Fox Chase Cancer Center.

Why Should Someone Pursue a Fellowship in Oncology?

November 25, 2021

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss what brought Dr. Nardello to the breast cancer field, what made him decide to pursue an oncology fellowship, and what residents should think about when choosing a fellowship location.

OncLive® Honors 14 Cancer Care Pioneers With Giants Awards

November 10, 2021

The 9th Annual Giants of Cancer Care® awards ceremony was a featured event at the 39th Annual CFS®: Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow®, hosted by Physicians’ Education Resource® LLC.

Key Advances Showcase the Potential of Precision Medicine in NSCLC

October 05, 2021

The sustainability of next-generation sequencing will be dependent on the implementation of thorough informatics and infrastructure that can support the integration of genomic results into electronic medical records.

Fox Chase’s Camille Ragin Awarded SPORE Grant to Examine Racial Differences in Risk for Head and Neck Cancer Patients

August 30, 2021

Fox Chase Cancer Center researcher Camille Ragin, PhD, MPH, was recently awarded a Specialized Program of Research Excellence grant of $50,000 for a pilot project examining differences in risk and disease course for Black versus white head and neck cancer patients.

Radiation Strategies Blaze a Trail for Better Outcomes in CNS Cancers and Beyond

May 21, 2021

Stephanie E. Weiss, MD, FASTRO and Eric M. Horwitz, MD, FABS, FASTRO, discuss ways to leverage radiation in the treatment of central nervous system metastases, areas of active investigation, and different available strategies that are improving outcomes for patients with cancer.

Ibrutinib Plus Venetoclax Results in High Residual Disease Eradication in CLL Model

May 17, 2021

The combination of ibrutinib and venetoclax were found to act on distinct subpopulations of chronic lymphocytic leukemia that have different proliferative capacities in an ex vivo model of the disease, suggesting that the dual-targeted approach has the potential to eradicate residual disease in patients with CLL.

Immunotherapy Makes Waves in Gastroesophageal and Gastric Cancers

March 24, 2021

Namrata (Neena) Vijayvergia, MD, discusses the emerging role of immunotherapy in resectable and metastatic esophageal and gastric cancers, as well as key nuances that could complicate these agents’ utility in clinical practice.

NCCN Guidelines for Gastric and Esophageal Cancers Updates Encompass Immunotherapy, TKIs Across Settings

March 20, 2021

Key updates to the National Comprehensive Cancer Network guidelines for gastric and esophageal cancers include the incorporation of immune checkpoint inhibitors spanning settings in patients with gastroesophageal cancer, the inclusion of fam-trastuzumab deruxtecan-nxki for those with HER2-positive gastric cancer, and the addition of recommended ramucirumab combinations for use in second- or later-line settings.

Borghaei and Gunuganti Break Down the Elements of Treatment Selection in NSCLC

December 17, 2020

In our exclusive interview, Dr. Borghaei and Dr. Gunuganti discuss patient selection for frontline immunotherapy, combination immunotherapy, and chemoimmunotherapy in NSCLC, the importance of PD-L1 expression, and emerging agents that are coming down the pike.